Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644108 | 0.81 | DPP4 (0.54) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL14921971 | 0.81 | DPP4 (0.52) | DPP4DPP8DPP9DPP7ACE | |
| Phosphoric Acid SCHEMBL15024109 | 0.77 | DPP4 (0.54) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL1289271 | 0.72 | DPP4 (0.56) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL14922003 | 0.72 | DPP4 (0.56) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL30970560 | 0.71 | DPP4 (0.62) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL28030532 | 0.71 | DPP4 (0.60) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3697380 | 0.70 | DPP4 (0.65) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL5138244 | 0.70 | DPP4 (0.47) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL15206677 | 0.70 | DPP4 (0.65) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289276-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC CONVERSION | CADILA HEALTHCARE LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| EP-2625179-A2 | PROCESS FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC CONVERSION | Cadila Healthcare Limited (IN) | 2013-08-14 | — | — | EP | disclosed |
| WO-2013065066-A1 | PROCESSES FOR PREPARING 4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6- DIHYDRO [L,2,41-TRIAZOLO[43-A]PYRAZIN-7(8H)-YL]-L-(2,4,5- TRIFLUOROPHENYL)BUTAN-2-AMINE | CADILA HEALTHCARE LIMITED (IN) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012046254-A2 | PROCESS FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC CONVERSION | CADILA HEALTHCARE LIMITED (IN) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289276-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC CONVERSION | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 7/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.